TACROLIMUS- tacrolimus capsule
BPI LABS LLC
- Increased risk of development of lymphoma and other malignancies, particularly of the skin, due to immunosuppression [see Warnings and Precautions ( 5.2)].
- Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections [ see Warnings and Precautions ( 5.3, 5.4, 5.5)].
- Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [ see Warnings and Precautions ( 5.1)].
Tacrolimus Capsules is indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. It is recommended that tacrolimus be used concomitantly with azathioprine or mycophenolate mofetil (MMF) and adrenal corticosteroids [ see Clinical Studies ( 14.1)] . Therapeutic drug monitoring is recommended for all patients receiving tacrolimus [ see Dosage and Administration ( 2.6)].
Tacrolimus Capsules is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. It is recommended that tacrolimus be used concomitantly with adrenal corticosteroids [ see Clinical Studies ( 14.2)]. Therapeutic drug monitoring is recommended for all patients receiving tacrolimus[ see Dosage and Administration ( 2.6)].
Tacrolimus Capsules is indicated for the prophylaxis of organ rejection in patients receiving allogeneic heart transplants. It is recommended that tacrolimus capsules be used concomitantly with azathioprine or mycophenolate mofetil (MMF) and adrenal corticosteroids [ see Clinical Studies ( 14.3)]. Therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules [ see Dosage and Administration ( 2.6)].
Tacrolimus Capsules should not be used simultaneously with cyclosporine [ see Dosage and Administration ( 2.5)].
Use with sirolimus is not recommended in liver and heart transplant. The safety and efficacy of tacrolimus with sirolimus has not been established in kidney transplant [ see Warnings and Precautions ( 5.12)].
Intravenous use reserved for patients who cannot tolerate capsules orally.
The initial oral dosage recommendations for adult patients with kidney, liver or heart transplants along with recommendations for whole blood trough concentrations are shown in Table 1. The initial dose of tacrolimus should be administered no sooner than 6 hours after transplantation in the liver and heart transplant patients. In kidney transplant patients, the initial dose of tacrolimus may be administered within 24 hours of transplantation, but should be delayed until renal function has recovered. For blood concentration monitoring details [ see Dosage and Administration ( 2.6 )]
Table 1. Summary of Initial Oral Dosage Recommendations and Observed Whole Blood Trough Concentrations in Adults
|Patient Population|| Recommended Tacrolimus Initial Oral Dosage |
Note: daily doses should be administered as two divided doses, every 12 hours
|Observed Tacrolimus Whole Blood Trough Concentrations|
|Adult kidney transplant patients||month 1-3: 7-20 ng/mL|
|In combination with azathioprine||0.2 mg/kg/day||month 4-12: 5-15 ng/mL|
|In combination with MMF/IL-2 receptor antagonist a||0.1 mg/kg/day||month 1-12: 4-11 ng/mL|
|Adult liver transplant patients||0.10-0.15 mg/kg/day||month 1-12: 5-20 ng/mL|
|Adult heart transplant patients||0.075 mg/kg/day||month 1-3: 10-20 ng/mL
month ≥4: 5-15 ng/mL
a) In a second smaller trial, the initial dose of tacrolimus was 0.15-0.2 mg/kg/day and observed tacrolimus concentrations were 6-16 ng/mL during month 1-3 and 5-12 ng/mL during month 4-12 [ see Clinical Studies ( 14.1)].
Dosing should be titrated based on clinical assessments of rejection and tolerability. Lower tacrolimus dosages than the recommended initial dosage may be sufficient as maintenance therapy. Adjunct therapy with adrenal corticosteroids is recommended early post-transplant.
The data in kidney transplant patients indicate that the Black patients required a higher dose to attain comparable trough concentrations compared to Caucasian patients Table 2.
|Time After Transplant|| Caucasian |
| Black |
|Dose (mg/kg)|| Trough Concentrations |
| Dose |
|Trough Concentrations (ng/mL)|
Initial Dose – Injection
Tacrolimus injection should be used only as a continuous IV infusion and when the patient cannot tolerate oral administration of tacrolimus capsules. Tacrolimus injection should be discontinued as soon as the patient can tolerate oral administration of tacrolimus, usually within 2-3 days. In a patient receiving an IV infusion, the first dose of oral therapy should be given 8-12 hours after discontinuing the IV infusion.
The observed trough concentrations described above pertain to oral administration of tacrolimus only; while monitoring tacrolimus concentrations in patients receiving tacrolimus injection as a continuous IV infusion may have some utility, the observed concentrations will not represent comparable exposures to those estimated by the trough concentrations observed in patients on oral therapy.
The recommended starting dose of tacrolimus injection is 0.03-0.05 mg/kg/day in kidney and liver transplant and 0.01 mg/kg/day in heart transplant given as a continuous IV infusion. Adult patients should receive doses at the lower end of the dosing range. Concomitant adrenal corticosteroid therapy is recommended early post-transplantation.
Anaphylactic reactions have occurred with injectables containing castor oil derivatives, such as Tacrolimus injection [ see warnings and Precautions ( 5.11)]
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.